Rosuvastatin in daily clinical practice – examples of use Case report
Article Sidebar
Published:
Jun 30, 2017
Keywords:
rosuvastatin, safety of therapy, drug interactions
Main Article Content
Abstract
Statins are the most commonly used class of drugs in the treatment of lipid disorders and evidences for lipid reduction and improved outcomes through statin therapy are strong and clear. Rosuvastatin has the most potent lipid-lowering effect of all the preparations currently available on the market. It is well tolerated and safe. The article presents 2 clinical cases in which rosuvastatin has been included in the treatment.
Article Details
How to Cite
Barylski , M. (2017). Rosuvastatin in daily clinical practice – examples of use. Medycyna Faktow (J EBM), 10(2(35), 158-161. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2158
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Catapano A.L., Graham I., De Backer G. et al.; Task Force Members; Additional Contributor: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016; 37(39): 2999-3058.
2. Banach M., Rysz J., Barylski M.: Rosuwastatyna – co już wiemy, czego wciąż oczekujemy? W: Banach M., Filipiak K.J., Opolski G.: Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 155-176.
3. Brewer H.B. Jr.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003; 92(4B): 23K-29K.
4. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of the intensive statin regiments on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
5. Bellosta S., Paoletti R., Corsini A.: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(supl. 1): III50-III57.
6. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Banach M., Filipiak K.J., Opolski G. (red.): Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 403-424.
2. Banach M., Rysz J., Barylski M.: Rosuwastatyna – co już wiemy, czego wciąż oczekujemy? W: Banach M., Filipiak K.J., Opolski G.: Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 155-176.
3. Brewer H.B. Jr.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003; 92(4B): 23K-29K.
4. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of the intensive statin regiments on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
5. Bellosta S., Paoletti R., Corsini A.: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(supl. 1): III50-III57.
6. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Banach M., Filipiak K.J., Opolski G. (red.): Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 403-424.